People: ACADIA Pharmaceuticals Inc (ACAD.OQ)

ACAD.OQ on NASDAQ Stock Exchange Global Select Market

1 Dec 2020
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Ridloff, Elena 

Ms. Elena H. Ridloff serves as Executive Vice President, Chief Financial Officer of the Company. She is our Executive Vice President, Chief Financial Officer. Ms. Ridloff was previously Senior Vice President, Investor Relations and Interim Chief Financial Officer and has been with our company since April 2018. Ms. Ridloff joined us from Alexion Pharmaceuticals, Inc., where she served as Executive Director, Investor Relations from April 2014 to January 2016 and Vice President, Investor Relations from January 2016 to March 2018, and served as a member of Alexion’s Operating Committee. While at Alexion, Ms. Ridloff was responsible for building and leading an investor relations function. Prior to joining Alexion, Ms. Ridloff served as the Chief Executive Officer and Managing Member of BIOVISIO, an independent consulting firm providing strategic, financial and investor relations counsel to the life sciences industry, from January 2012 to April 2014. Ms. Ridloff also served as Managing Director at Maverick Capital, a hedge fund responsible for investments in the biotechnology, pharmaceutical, medical device and life science sectors, from July 2005 to January 2012. Ms. Ridloff earned her B.A. in history and sociology of science from the University of Pennsylvania, and is a Chartered Financial Analyst.

Basic Compensation

Total Annual Compensation, USD 444,026
Restricted Stock Award, USD 652,165
Long-Term Incentive Plans, USD --
All Other, USD 894,675
Fiscal Year Total, USD 1,990,870

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 36,000 1,218,600.00
Name Fiscal Year Total

Stephen Biggar


Srdjan Stankovic


Stephen Davis


Elena Ridloff


Austin Kim


Gudarz Davar

As Of  31 Dec 2019